NCT00263016View on ClinicalTrials.gov

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

PHASE2TerminatedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

May 31, 2005

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Docetaxel

Trial Locations (1)

Unknown

Sanofi-aventis, Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00263016 - Docetaxel in Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter